Sareum Holdings discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases. The Company's drug development programmes aim to improve outcomes for patients with serious medical conditions and where current therapies are inadequate. Sareum Holdings develops therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The Company’s product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, TYK2 kinase-autoimmune diseases and TYK2 kinase-cancer.
Type | Public | |
Founded | 2003 | |
HQ | Pampisford, GB | Map |
Website | sareum.com |
GBP | |
---|---|
Revenue (FY, 2007) | 2.5m |
Gross profit (FY, 2007) | 618.1k |
Gross profit margin (FY, 2007), % | 25% |
Net income (FY, 2007) | (527.4k) |
EBIT (FY, 2007) | (734.6k) |
Market capitalization (7-Apr-2021) | 60.5m |
Closing stock price (7-Apr-2021) | 0.0 |
Cash (30-Jun-2019) | 919.0k |
EV | 59.5m |
GBP | FY, 2007 |
---|---|
Revenue | 2.5m |
Cost of goods sold | 1.9m |
Gross profit | 618.1k |
Gross profit Margin, % | 25% |
GBP | FY, 2007 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|
Cash | 660.3k | 700.6k | 1.5m | 1.3m | 2.3m | 1.4m | 919.0k |
Accounts Receivable | 472.4k | ||||||
Current Assets | 1.5m | 1.1m | 1.7m | 1.5m | 2.4m | 1.8m | 1.2m |
GBP | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|
Cash From Operating Activities | (785.3k) | (644.2k) | (678.0k) | 843.9k | (1.6m) |
Cash From Investing Activities | (970.8k) | 67.6k | (592.7k) | 216.0k | 3.7k |
Cash From Financing Activities | 2.0m | 1.4m | 1.0m | (6.9k) | 658.3k |
Net Change in Cash | 279.0k | 779.4k | (227.4k) | 1.1m | (930.2k) |
Sareum Holdings has 1.26k Twitter Followers. The number of followers has increased 0.3% month over month and increased 1.1% quarter over quarter
409
Tweets
430
Following
1.3k
Followers
1
Tweets last 30 days
0
Avg. likes per Tweet
100%
Tweets with engagement
When was Sareum Holdings founded?
Sareum Holdings was founded in 2003.
Who are Sareum Holdings key executives?
Sareum Holdings's key executives are Stephen Parker Dphil, John Reader and Clive Birch.
How many employees does Sareum Holdings have?
Sareum Holdings has 6 employees.
What is Sareum Holdings revenue?
Latest Sareum Holdings annual revenue is £2.5 m.
What is Sareum Holdings revenue per employee?
Latest Sareum Holdings revenue per employee is £411.8 k.
Who are Sareum Holdings competitors?
Competitors of Sareum Holdings include Xilio Therapeutics, Karo Pharma and Luye Pharma.
Where is Sareum Holdings headquarters?
Sareum Holdings headquarters is located at 2a Langford Arch London Rd, Pampisford.
Where are Sareum Holdings offices?
Sareum Holdings has an office in Pampisford.
How many offices does Sareum Holdings have?
Sareum Holdings has 1 office.
Receive alerts for 300+ data fields across thousands of companies